Aβ-Cu复合物与Aβ纤丝对小胶质细胞激活作用比较研究

目的:比较具有氧化还原活性的过渡金属离子Cu~(2+)(Cu)诱导形成的Aβ聚集物(Aβ-Cu复合物)与Aβ自聚集形成的纤丝(Fibrillar Aβ,f Aβ)对小胶质细胞激活作用的差异。方法:制备Aβ-Cu复合物和fAβ,利用小鼠BV-2小胶质细胞株,分别以不同浓度的Aβ-Cu复合物和fAβ于37℃刺激24 h,检测细胞上清液中的TNF-α(Tumor necrosis factor-α)、NO(Nitric oxide)以及H_2O_2(Hydrogen Peroxide)的含量。分别收集Aβ-Cu复合物和f Aβ作用24 h后的大鼠原代小胶质细胞条件培养液,通过观察该条件培养液对大鼠原代海马神经元细胞活力的影响,评价小胶质细胞介导的间接神经元毒性。结果:(1)在不引起直接神经毒性剂量(2.5μM)下,Aβ-Cu复合物激活小胶质细胞释放TNF-α(P0.01)、NO(P0.05)以及H_2O_2(P0.05)的作用强于f Aβ。(2)在此剂量下,Aβ-Cu复合物通过激活小胶质细胞引起的间接神经元毒性强于fAβ(P0.05)。结论:与fAβ相比,非神经毒性剂量的Aβ-Cu复合物对于小胶质细胞具有更强的激活作用,并由此引发更为明显的神经元毒性。     

Aβ-Cu(Ⅱ)复合物与阿尔茨海默病的关系

β-淀粉样肽(amyloid peptide β,Aβ)在脑内沉积并与Cu(Ⅱ)螯合形成AB—Cu(Ⅱ)复合物,该复合物诱导活性氧形成并造成神经细胞损伤,这可能是阿尔茨海默病(AD)发生与发展的主要机制之一;以此为基础．探讨使用抗氧化剂及金属螯合剂降低Aβ神经毒性,可能是探索预防AD发生和减缓AD发展的一个新途径。     

小胶质细胞TREM2调控阿尔茨海默病发生的机制研究进展

阿尔茨海默病(AD)是最常见的一种神经退行性疾病,具有多因异质性的特点,具体致病原因尚不清晰。小胶质细胞是常驻于中枢神经系统中的巨噬细胞,负责细胞吞噬、突触修剪、能量代谢等。髓系细胞触发受体2 (TREM2)是一种主要存在于小胶质细胞表面的受体,对小胶质细胞的功能稳态至关重要。TREM2 R47H和R62H两个变异体会增加个体晚发性AD风险,该发现使TREM2成为AD领域一个新的研究热点。本文主要围绕小胶质细胞TREM2的结构、表达调控、信号转导、功能及其在AD中的病理学作用等多个方面进行系统性综述,以期在加深理解TREM2的同时,为深入研究小胶质细胞TREM2表达和功能异常在AD发生发展中的作用和分子机制提供参考。     

小胶质细胞的活化与阿尔茨海默病

小胶质细胞是中枢神经系统中一种巨噬细胞样吞噬细胞,具有重要的免疫细胞作用。它与阿尔茨海默病（AD）的发生和发展有关,目前认为它可能通过两种机制起作用。其一是伴随着阿尔茨海默病的特征性病理改变,小胶质细胞活化,进而引起局部炎症反应;其二是它参与了β淀粉样蛋白的清除。大量研究结果提示这两个过程是密切联系的,即：β淀粉样蛋白吸引并激活小胶质细胞,活化后小胶质细胞的一部分分泌炎症因子,引起炎症反应;而另一部分则具有吞噬β淀粉样蛋白的作用。关于这方面的研究目前还没有一致意见。     

Cu2+-Aβ 复合物与Aβ 单体诱导神经元 H2O2 释放作用的比较研究

目的:比较不同摩尔比Cu~(2+)-Aβ复合物与Aβ单体诱导神经元H_2O_2释放作用的差异。方法:制备不同摩尔比(0.1-5)的Cu~(2+)-Aβ复合物,通过检测硫磺素T(Thioflavin T,Th T)荧光强度考察Cu~(2+)对Aβ纤丝形成的影响。利用原代培养的大鼠海马神经元细胞,分别以不同摩尔比Cu~(2+)-Aβ复合物,不同浓度Cu~(2+)-Aβ复合物(摩尔比为1),以及Aβ单体和Cu~(2+)处理细胞,检测培养上清中的H_2O_2含量;分离线粒体,分别检测不同浓度Cu~(2+)-Aβ复合物(摩尔比为1),以及Aβ单体和Cu~(2+)处理后H_2O_2的释放;观察不同摩尔比Cu~(2+)-Aβ复合物,不同浓度Cu~(2+)-Aβ复合物(摩尔比为1),以及Aβ单体和Cu~(2+)对神经元细胞活力的影响。结果:(1)Th T荧光试验结果表明,Cu~(2+)与Aβ(10μM)摩尔比为1~5范围内可明显抑制Aβ纤丝形成。(2)Cu~(2+)-Aβ复合物(摩尔比为1~5;Aβ浓度为10μM)以及摩尔比为1的Cu~(2+)-Aβ复合物(Aβ浓度分别为5,10μM)可显著诱导神经元释放H_2O_2;另外,摩尔比为1时,Cu~(2+)-Aβ复合物还可诱导神经元线粒体内H_2O_2释放;上述作用均强于Aβ单体或Cu~(2+)。(3)Cu~(2+)-Aβ复合物(摩尔比为1~5)可显著降低神经元细胞活力,该作用强于Aβ单体或Cu~(2+)。结论:与Aβ单体相比,Cu~(2+)-Aβ复合物诱发神经元细胞及其线粒体释放H_2O_2作用更强,并诱发更为明显的神经元毒性。提示Cu~(2+)与Aβ之间的配位结合可能增强其引发活性氧释放以及神经元毒性反应;Cu~(2+)-Aβ复合物引发的活性氧可能主要来自线粒体。     

维生素C保护Aβ1-40Cu(Ⅱ)复合物引起的神经元氧化损伤

老年斑中存在大量β 淀粉样蛋白（β-amyloid, Aβ）是老年痴呆症（Alzheimer′s disease, AD）的重要病理特征.大量数据表明,Aβ上具有与过渡态金属离子共价结合的位点,二者能结合成为寡聚复合物. Aβ_1-40Cu（Ⅱ）复合物通过Cu²⁺的还原催化O₂产生H₂O₂但反应机制不清.本文尝试以天然抗氧化剂维生素C（VC）来对抗Aβ_1-40及Aβ_1-40Cu（Ⅱ）复合物产生的H₂O₂对原代培养的神经细胞的毒性.结果表明,VC能够起到显著的保护作用,其有效浓度为1mmol/L.本文用胞外乳酸脱氢酶泄漏量和H₂O₂生成量的数据证实了细胞存活率（MTT实验）的实验结果.这些结果表明,Aβ_1-40Cu（Ⅱ）复合物能够释放更多的H₂O₂,引发细胞膜破裂并最终引起细胞死亡.加入VC后,神经元受到的损伤较轻,提示VC在保护细胞免受氧化损伤方面发挥了重要作用.     

小胶质细胞与阿尔茨海默病

国内外对阿尔茨海默病（Alzheimer’s disease,AD）神经元病理和神经胶质细胞病理机制进行了大量探索,小胶质细胞（microglia,MG）是中枢神经系统的免疫细胞,在致炎因素作用下它被激活成反应性MG,反应性MG既具有保护神经元的作用,也能分泌细胞毒因子、补体蛋白而损害神经元。尽管目前AD发病机理还不清楚,但大多数学者认为β淀粉样蛋白（Aβ）沉积激活MG引起的炎症反应是AD的核心病理机制。     

阿尔茨海默病中Toll样受体与小胶质细胞的关系

阿尔茨海默病(Alzheimer’s disease,AD)是老年人常见的一种神经退行性疾病。目前AD的发病机制还不是很清楚,但大多数学者认为淀粉样蛋白沉积激活神经胶质细胞所导致的炎症反应是其核心病理机制,其中小胶质细胞是主要的炎症细胞。近期研究表明Toll样受体(Toll-like receptor,TLR)在小胶质细胞的激活过程中发挥着一定的作用。本文主要就近年来AD发病过程中TLR与小胶质细胞之间关系方面的研究进行综述。     

小胶质细胞在阿尔茨海默病中的作用

近年来,小胶质细胞在阿尔茨海默病发生和发展中的作用成为一个新的研究热点.由于它在该病中的作用具有"两面性"的性质,因此如何平衡两方面之间的关系成为摆在研究者面前的一个重要课题.而突破这一课题的关键在于对β淀粉样蛋白与小胶质细胞相互作用机理的研究.本文主要讨论了各种β淀粉样蛋白与小胶质细胞的相互作用和它们的机理.综述了到目前为止为平衡这两方面作用所作的工作,主要是抗炎性药物和细胞因子作用机理的研究.     

小胶质细胞的神经递质受体在阿尔茨海默病中的作用

阿尔茨海默病(Alzheimer's disease,AD)是一种因蛋白错误折叠、聚积影响神经细胞功能,从而导致认知功能下降、行为异常的神经退行性疾病.小胶质细胞是中枢神经系统(central nervous system,CNS)中重要的免疫细胞之一,在AD病理过程中,根据其激活状态的不同小胶质细胞发挥神经保护或神经...     

姜黄素对小胶质细胞的活化的影响

目的:研究姜黄素对脂多糖引起的小胶质细胞活化状态的影响,并探讨TOLR4受体在其中的作用。方法:采用体外培养N9小鼠小胶质细胞系,脂多糖作为刺激,激活小胶质细胞。采用ELISA法检测小胶质细胞培养基中TNF-α、IL-1β和IL-6的含量;相差显微镜观测细胞形态;免疫细胞化学和western blot观测小胶质细胞TOLR4受体表达情况。结果:与对照组相比,暴露于100ng/ml脂多糖24 h的小胶质细胞促炎症因子TNF-α、IL1β和IL-6释放量明显增加(P0.05),姜黄素浓度为10μM时,可显著减少小胶质细胞释放TNF-α、IL-1β和IL-6(P0.05),此外,姜黄素还可改善小胶质细胞形态,并降低暴露于脂多糖中的小胶质细胞TOLR4受体的表达。结论:姜黄素可能通过抑制TOLR4表达,减轻了脂多糖对小胶质细胞的激活。     

Attenuation of Dichlorvos-Induced Microglial Activation and Neuronal Apoptosis by 4-Hydroxy TEMPO

The neurotoxic consequences of acute high-level as well as chronic low-level organophosphates exposure are associated with a range of abnormalities in nerve functions. Previously, we have shown that after 24 h of dichlorvos exposure, microglia become activated and secrete pro-inflammatory molecules like nitric oxide, tumour necrosis factor-α and interleukin-1β. Here, we extended our findings and focused on the neuronal damage caused by dichlorvos via microglial activation. For this, neurons and microglia were isolated separately from 1-day-old Wistar rat pups. Microglia were treated with dichlorvos for 24 h and supernatant was collected (dichlorvos-induced conditioned medium, DCM). However, when 4-hydroxy TEMPO (4-HT) pretreatment was given, we observed significant attenuation of dichlorvos-induced microglial activation; we also collected the supernatant of this culture (4-HT + DCM, TDCM). Next, we checked the effects of DCM on neurons and found heavy loss in viability as evident from NF-H immunostaining and MTT results, whereas dichlorvos alone-treated neurons showed comparatively less damage. However, we observed significant increase in neuronal viability when cells were treated with TDCM. Semi-quantitative PCR and western blot results revealed significant increase in p53, Bax and cytochrome c levels along with caspase 3 activation after 24 h of DCM treatment. However, TDCM-treated neurons showed significant decrease in the expression of these pro-apoptotic molecules. Taken together, these findings suggest that 4-HT can significantly attenuate dichlorvos-induced microglial activation and prevent apoptotic neuronal cell death.     

Rutin Supplementation in the Diet has Protective Effects Against Toxicant-Induced Hippocampal Injury by Suppression of Microglial Activation and Pro-Inflammatory Cytokines

Aims Rutin is one of the flavonoids that has many beneficial effects on the health. Previously, we showed that rutin has a protective effect on trimethyltin (TMT)-induced memory dysfunction in rats. The aim of this study was to investigate the protective effects of rutin on TMT-induced hippocampal injury and the time course profiles of these effects in rats. Methods Four-week-old male Sprague-Dawley (SD) rats were fed chow with or without rutin (0.75%) during the experimental period and were administered with a single dose of TMT (8.5 mg/kg b.w., p.o.) or vehicle at 6 weeks of age. The rats were sacrificed 5, 10, or 20 days after the TMT administration and then histological and molecular examinations of the hippocampus were performed. Results Rutin supplementation suppressed the TMT-induced decrease in the number of hippocampal pyramidal neurons 20 days after TMT administration. The TMT-induced up-regulation of the mRNA expression levels of reactive microglia marker and pro-inflammatory cytokines were reversed by rutin supplementation 10 or 20 days after the TMT administration. Conclusions These results suggested that the neuroprotective effect of rutin on TMT-induced spatial memory impairment could be attributable to its inhibitory effect against microglial activation and its role in synapse formation via neurotrophic factors in the hippocampus.     

Absence of CD14 Delays Progression of Prion Diseases Accompanied by Increased Microglial Activation

Prion diseases are fatal neurodegenerative disorders characterized by accumulation of PrP^Sc, vacuolation of neurons and neuropil, astrocytosis, and microglial activation. Upregulation of gene expressions of innate immunity-related factors, including complement factors and CD14, is observed in the brains of mice infected with prions even in the early stage of infections. When CD14 knockout (CD14^−/−) mice were infected intracerebrally with the Chandler and Obihiro prion strains, the mice survived longer than wild-type (WT) mice, suggesting that CD14 influences the progression of the prion disease. Immunofluorescence staining that can distinguish normal prion protein from the disease-specific form of prion protein (PrP^Sc) revealed that deposition of PrP^Sc was delayed in CD14^−/− mice compared with WT mice by the middle stage of the infection. Immunohistochemical staining with Iba1, a marker for activated microglia, showed an increased microglial activation in prion-infected CD14^−/− mice compared to WT mice. Interestingly, accompanied by the increased microglial activation, anti-inflammatory cytokines interleukin-10 (IL-10) and transforming growth factor β (TGF-β) appeared to be expressed earlier in prion-infected CD14^−/− mice. In contrast, IL-1β expression appeared to be reduced in the CD14^−/− mice in the early stage of infection. Double immunofluorescence staining demonstrated that CD11b- and Iba1-positive microglia mainly produced the anti-inflammatory cytokines, suggesting anti-inflammatory status of microglia in the CD14^−/− mice in the early stage of infection. These results imply that CD14 plays a role in the disease progression by suppressing anti-inflammatory responses in the brain in the early stage of infection.